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Summary 
Considerable evidence has associated the expression of matrix metalloproteinases (MMPs) with 
the degradation of cartilage and bone in chronic conditions such as arthritis. Direct evaluation 
of MMPs'  role  in vivo has  awaited  the development of MMP  inhibitors with  appropriate 
pharmacological properties. We have identified butanediamide, N4-hydroxy-2-(2-methylpropyl)- 
Nl-[2-[[2-(morpholinyl)ethyl]-,[S-(K*,S*)] (GI168) as a potent MMP inhibitor with sufficient 
solubility and stability to permit evaluation in an experimental model of chronic destructive arthritis 
(adjuvant-induced arthritis)  in  rats.  In  this  model,  pronounced acute and chronic synovial 
inflammation, distal tibia and metatarsal marrow hyperplasia associated with osteoclasia, severe 
bone and cartilage destruction, and ectopic new bone growth are well developed by 3 wk after 
adjuvant injection. Rats were injected with Freund's adjuvant on day 0. GI168 was was administered 
systemically from days 8 to 21 by osmotic minipumps implanted subcutaneously.  GI168 at 6, 
12, and 25 mg/kg per d reduced ankle swelling in a dose-related fashion. Radiologicai and histological 
ankle  joint evaluation on day 22 revealed a profound dose related inhibition of bone and cartilage 
destruction in treated rats relative to rats receiving vehicle alone. A significant reduction in edema, 
pannus formation, periosteal new bone growth and the numbers of adherent marrow osteoclasts 
was also noted. However, no significant decrease in polymorphonuclear  and mononuclear leukocyte 
infiltration of synovium and marrow hematopoietic cellularity was seen. This unique profile of 
antiarthritic activity indicates that GI168 is osteo- and chondro-protective, and it supports a direct 
role for MMP in cartilage and bone damage and pannus formation in adjuvant-induced arthritis. 
I 
n rheumatoid arthritis, pain and swelling can generally be 
controlled by currently available drugs, but it has been diffi- 
cult to halt the progressive joint destruction associated with 
this disease. Therefore, much effort has been directed at more 
specific inhibition of the biochemical mechanisms under- 
lying joint destruction. The enzymes most often implicated 
in the joint destruction are the matrix metalloproteinases 
(MMPs). 1 MMPs are a family of zinc-dependent endopepti- 
dases that degrade components of the extracellular  matrix 
(1). MMPs fall into three classes based on their substrate 
1  Abbreviation used in this paper: MMP. matrix metalloproteinase. 
specificity. Interstitial (MMP-1) and neutrophil collagenase 
(MMP-8) are the only enzymes known to degrade collagen 
types I and II at neutral pH. Collagen type I is the major 
structural protein of bone whereas collagen type II is a major 
component of cartilage. Gelatinases (MMP-2 and 9) degrade 
collagen types IV and V and denatured protein. Gelatinase 
works in concert with collagenase  in that collagen type I 
fragmented by collagenase can unwind and become a sub- 
strate for gelatinase. Stromelysin (MMP-3) degrades fibronectin 
and glycoproteins and proteoglycans, a key component of car- 
tilage. 
There has been considerable work in in vitro systems im- 
plicating MMPs in connective tissue breakdown. Treatment 
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stimulates tissue degradation and MMP secretion into the 
media (2). Treatment of bone with parathyroid hormone or 
1,25-dihydroxy vitamin D3 in vitro causes bone resorption 
and MMP secretion into the media (3,  4).  Stimulation of 
proteoglycan release from explants of rabbit articular carti- 
lage stimulated with retinoid, IL-1 or LPS in vitro (5)  is 
blocked by synthetic MMP inhibitors. MMP inhibitors block 
proteoglycan release  from cartilage explants isolated from 
rabbits that had undergone prior meniscectomy (6).  MMP 
inhibitors reduce the loss of collagen and proteoglycan from 
IL-l-treated bovine nasal cartilage (7) and human articular 
cartilage (8). Parathyroid hormone-induced resorption of  bone 
in the mouse calvaria was also inhibited by a synthetic MMP 
inhibitor (9). 
In contrast to the in vitro situation, there are only indirect 
lines of evidence supporting a destructive role for MMPs in 
vivo.  It is clear  that the mRNA and protein levels of col- 
lagenase (10-13), gelatinase (2, 13), and stromelysin (2, 10-14) 
are elevated in the arthritic  joints of  both animals and humans. 
However, mRNA and protein level measurements don't dis- 
tinguish between active and inactive forms ofMMPs. MMPs 
are synthesized and secreted  as latent zymogens and must 
be cleaved to the active form outside the cell (1). MMP ac- 
tivity is  also  regulated by the endogenous inhibitors a2- 
macroglobulin and  tissue inhibitors of metalloproteinases 
(TIMP-1 and TIMP-2) (1). Thus, both the degree of zymogen 
activation and inhibitor concentrations can impact MMP ac- 
tivity in vivo.  It is also possible  that other enzymes might 
play significant roles in joint destruction. For example, pos- 
sible low pH microenvironments in the arthritic  joint would 
allow cysteine proteinases to operate in a collagenolytic mode 
(15-17). Besides consideration of the enzymes degrading the 
matrix, one must consider that products of matrix degrada- 
tion could influence the inflammation process  in vivo.  For 
example, peptide products from the degradation of collagen, 
gelatin, and fibronectin are chemotactic for a variety of inflam- 
matory cells (18-21). 
Here we describe an MMP inhibitor with sufficient solu- 
bility to permit continuous systemic administration in vivo. 
Administration of this inhibitor showed dramatic inhibition 
of connective tissue destruction in the joints of rats with 
adjuvant-induced arthritis. These data imply that MMP in- 
hibitors could be developed  for therapeutic use to halt de- 
struction in rheumatoid arthritis. 
Materials  and Methods 
Animals.  Male Lewis rats  (160-170 g)  from Charles giver 
Laboratories (Raleigh, NC) grew to "~240-250 g before the injec- 
tion of adjuvant (see below). The animals were free of pathogenic 
viruses as determined by a standard viral titer screen (Microbiolog- 
ical Associates, Bethesda, MD). 
Induction and Measurement of Adjuvant Arthritis.  Freund's com- 
plete adjuvant was prepared by adding 100 mg Mycobacterium tuber- 
culosis (Difco Laboratories, Detroit, MI) to 15.6 ml heavy paraffin 
oil followed by addition of i  ml saline. The mixture was then 
emulsified  by pulsing for 90 s with a polytron (Brinkmann Instru- 
ments, Inc., Westbury, NY). Each rat was injected intradermally 
at the tail base with 300/zg of Mycobacterium in a 0.05-ml vol. 
Paw inflammation  was quantitated by measuring paw diameter  with 
calipers. 
MMP Inhibitor and Minipump Implantation.  The MMP inhib- 
itor butanediamide, N4-hydroxy-2-(2-methylpropyl)-Nl-[2-[[2-(4- 
morpholinyl)ethyl]amino]  2-oxo-l-(phenylmethyl)ethyl]-,  [S-(R*,S  *  )] 
(GI168), was synthesized in the Department of Medicinal Chem- 
istry at Glaxo Inc. GI168 was dissolved in DMSO and added to 
50 mM sodium citrate buffer, pH 4.0, giving a final DMSO con- 
centration of 20%. Rats were anesthetized with a constant flow 
of 2.5%  isoflurane, their backs were shaved, cleaned with Be- 
tadine  TM, two 14-d minipumps (model 2ML2; Alza Corp., Palo 
Alto, CA) were inserted subcutaneously into their backs, and the 
insertion sites were closed with wound clips. These pumps deliver 
5/A/h, so at the highest soluble drug concentration of 25 mg/ml, 
the pumps delivered 25 mg/kg/d. Controls received 50 mM so- 
dium citrate, pH 4.0, containing 20% DMSO. 
Radiological and Histological Scoring.  At the end of the experi- 
ment, paws were fixed in 10% buffered formalin and radiological 
plates were prepared. A section was then taken through the middle 
of the paw and stained with hematoxylin and eosin for histological 
analysis. The radiological plates were scored in a blind fashion by 
Dr. Richard L. Clark (University of North Carolina, Chapel Hill, 
NC) using a previously described scale from 0 (no damage) to 4 
(severe damage) for the parameters defined in Table 1 (22). Histo- 
logical effects  were also scored  in a blind fashion  from 0 (no damage) 
to 5 (very severe damage) by two independent observers for the 
parameters defined in Table 2. Differences  between the radiological 
and histological scores of vehicle-treated  and drug-treated rats were 
assessed using a one degree of freedom chi-square test. Type  I error 
rates of all tests were maintained at 5% using Sidak's method (23). 
MMP Assays.  Recombinant human collagenase  (MMP-1) and 
stromelysin  (MMP-3) were expressed in Escherichia  coli, purified  from 
inclusion bodies, and refolded at room temperature for 1 h before 
use. Human 92-kD gelatinase (MMP-9) was purified as described 
previously (24). Rat collagenase  was purified from rat uterus (25). 
Collagenase assays  were conducted in a buffer (200 mM NaC1, 50 
mM Tris, 5 mM CaC12, 20 M ZnSO4, pH 7.6) containing 0.05% 
Brij 35, 3 nM enzyme, and  100/~M of the chromogenic sub- 
strate Ac-Pro-Leu-GIy-SCH[CH2CH(CH3)2]  CO-Leu-Gly-OC2Hs 
(Bachem California, Torrance, CA) (26). Human 92-kD gelatinase 
was measured in assay  buffer containing 0.01% Brij 35, 1 nM en- 
zyme, and 10 #M of the fluorogenic substrate Dnp-Pro-Cha-Gly- 
Cys(Me)-His-Ala-Lys(Nma)-NH2 (24). Human stromelysin was 
measured in assay  buffer containing 0.05% Brij 35, 10 nM enzyme, 
and 10/~M of the fluorogenic  substrate Dnp-Pro-Gln-Gln-Phe-Lys- 
Arg-Lys(Nma)-NHv In all the assays described above, substrate 
concentrations are well below the Km so the ICso ~" Ki for the 
compounds. 
Plasma Assay of GI168.  GI168  was administered to untreated 
rats at 25 mg/kg per d by two 14-d minipumps implanted sub- 
cutaneously (see above). On day 4 and 12 of drug infusion, rats 
were killed by CO2 asphyxiation, blood was taken from the in- 
ferior vena cava, and plasma prepared and frozen at -20~  GI168 
was separated from plasma  by centrifugation through a 30,000-mol 
wt cut-off filter (model YMT-30; Amicon Corp., Beverly, MA) 
for 3 min at 1,500 g. Less than 20% of the plasma appeared as 
filtrate under these conditions. The plasma filtrate was then seri- 
ally  diluted and tested  for inhibition of  human coUagenase  (see MMP 
assays above). The filtrate dilution necessary for 50% inhibition 
of human collagenase activity was multiplied by the known ICs0 
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MMP Inhibition In Vitro and GI168 Delivery In Viva  GI168  -~  e.s 
inhibited  rat  collagenase with  an  ICs0 of 15 nM.  Against  -=  | 
human enzymes, GI168 was equipotent against collagenase 
8.0 
and gelatinase (ICs0  =  3 nM) but much less active against  7.s 
stromelysin  (ICs0  =  225  nM).  To check for inhibition  of 
gelatinase activity across species, zymograms were run using  r.0 
serum-free media from cell cultures  of human  LOX mela-  6.s 
noma, rat Mat Ly Lu prostate tumor, and mouse M27 Lewis 
lung carcinoma.  Zymograms were renatured and developed  6"06  8  1'0  12  14  16  18  20 
in the presence of 50 nM GI168.  Under  these conditions, 
gelatinases from all three cell lines were inactive (data not 
shown),  indicating  cross-species inhibition  of gelatinase at 
50 nM GI168. 
GI168 has poor oral bioavailability and a short plasma tl/z 
after subcutaneous injection (data not shown), so minipump 
delivery was evaluated.  At  its  maximum  solubility of 25 
rag/m1, GI168 was shown to be stable after storage for 2 wk 
at 37~  GI168 was then continuously administered to un- 
treated  rats  at  25  mg/kg  per  d  by implanting  two  14-d 
minipumps subcutaneously. On clays 4 and 12 after minipump 
implantation,  the plasma levels of GI168 were 223  _+  11 (n 
=  4) and  113  _  7 (n  =  4) nM, respectively. Since GI168 
shows <10% binding to plasma proteins (see Materials and 
Methods),  GI168 in the plasma is immediately available for 
inhibition of MMPs in vivo. Thus with minipump infusion, 
the steady-state plasma levels of unbound GI168 were 7- to 
15-fold above the IC50 for inhibition  of rat  collagenase in 
vitro. 
Effect of GI168 on Ankle Swelling.  In the adjuvant arthritis 
model,  the adjuvant was injected on day 0.  Ankles started 
to swell on days 9-10,  and cartilage and bone damage be- 
comes progressive from day 15 onward.  The inflammation 
and connective tissue damage is constant  up to ~, day 30, 
resulting in severe systemic disease and severe joint deformity 
(reviewed in references 27, 28). Given the constraints of the 
14-d minipump delivery system, two 14-d pumps were im- 
planted on day 8 and the experiment terminated on day 21. 
By day 21,  there had been 10 d of ankle swelling,  and the 
essential features of cartilage and bone damage were dearly 
evident. Oral indomethacin (1 mg/kg) once daily was used 
as a positive control for an antiinflammatory response. The 
effect of GI168 on ankle swelling is shown in Fig. 1. In rats 
with vehide-fiUed pumps, ankle diameter increased in a linear 
fashion from clays 8-15, with a plateau between days 15 and 
20. GI168 decreased ankle swelling in a dose-response manner 
with 25,  12,  and 6 mg/kg per d,  giving 50, 38, and 16% 
inhibition of ankle swelling on day 20, respectively. The indo- 
methacin control gave 54% inhibition of ankle swelling on 
day 20, as expected (Fig.  1). This experiment confirmed an 
initial  experiment  in  which  25  mg/kg  per  d  GI168  and 
Days  After  Adjuvant  Injection 
Figure 1.  Effect  of GI168 on adjuvant arthritis-induced ankle swelling 
in rats. Rats were implanted subcutaneously  with two 14-d minipumps 
on day 8 to continuously deliver the cited daily doses of G1168. Indo- 
methacin (indo)  was given orally  daily. Normal rats received  no treatment. 
Data represent mean +  SEM with 5-10 rats per group. 
1 mg/kg per d indomethacin inhibited ankle swelling by 50 
and 79%,  respectively (data not  shown). 
Effect of GI168 on Radiologicat Parameters of  Joint Damage. 
Representative radiographs of ankle joints from normal rats 
and rats treated with vehicle or GI168 after adjuvant injec- 
tion are  shown in Fig.  2. Compared to the vehicle-treated 
control, the ankle from the rat treated with GI168 had greater 
bone density, lacked focal areas of severe bone loss, and showed 
less  soft tissue swelling. 
Since  both  experiments  with  GI168  had  similar joint 
swelling, the ankles were combined for radiological and histo- 
logical scoring.  Radiological scoring of day 21 ankles is shown 
in  Table  1.  GI168  caused  a  dose-dependent  inhibition  of 
pathology in all five radiologic parameters, with even the lowest 
dose of 6 mg/kg per d causing a shift to less pathology in 
all parameters except edema (Table 1). The inhibition at 25 
and 12 mg/kg per d GI168 was statistically significant in all 
five parameters,  whereas at 6 mg/kg  per d,  the inhibition 
was only statistically significant  against bone marrow ero- 
sion and bone demineralization. 
Effect of GI168 on Histological Parameters of  Joint Damage. 
Representative photomicrographs of ankle joints from normal 
rats and rats treated with vehicle or GI168 after adjuvant in- 
jection are shown in Fig. 3. Joints of vehicle-treated arthritic 
rats  showed acute articular  distension  and  swelling.  There 
was increased synovial fluid that contained sloughed type A 
synovial cells, neutrophils, and fibrin strands. The joint cap- 
sule and subsynovial tissue were distended with edema and 
characterized by serous degeneration of the subsynovial adi- 
pose tissue with an infiltration of neutrophils with fewer lym- 
phocytes and histocytes. 
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of trabecular bone with the resultant enlarged medullary cavi- 
ties filled with hematopoietic precursors  and inflammatory 
cells (Fig. 3). This ongoing remodeling of trabecular bone 
was associated with marked periosteal, endosteal, and trabec- 
ular new bone formation. In the more severely  affected  joints, 
there was also osteoclastic resorption of epiphyseal bone and 
the subchondral bone plate. In these joints, cartilage resorp- 
tion by chondroclasts from the epiphyseal medullary cavity 
was also common. Cartilage loss was commonly seen at the 
margin of the joint in association  with progressive pannus 
formation. 
Several parameters  of connective tissue and inflammatory 
cellular changes were scored (Table 2). GI168 caused a dose- 
dependent inhibition of the events directly associated with 
bone destruction, even with the lowest dose of 6 mg/kg per 
d, causing a shift to less pathology in bone erosion (both 
marginal erosions and trabecular osteoclasia), the number of 
adherent osteoclasts, and periosteal new bone formation and 
remodeling (Table 2) consistent with the results of the radio- 
logical  scoring (Table 1). There was statistically  significant 
inhibition of the bone destruction parameters  at  12 and 25 
mg/kg per d, as well as significant protection against carti- 
lage destruction and pannus formation. With the low dose 
of GI168, only inhibition of periosteal new bone growth and 
remodeling was statistically  significant. 
Though GI168 significantly inhibited edema at the 25 and 
12 mg/kg per d dose, it was not uniformly successful in in- 
hibiting all the events associated  with soft tissue swelling (Table 
2). Neither dose of GI168 significantly reduced synovial lining 
necrosis, and only the high dose reduced synovial lining dis- 
tension. GI168 had no obvious effect on the degree of infiltra- 
tion of mononuclear leukocytes and PMNs into the  joint space 
or bone marrow cavities. In addition, instead of the serous 
degeneration of subsynovial and periarticular fat observed in 
the vehicle-treated  arthritic joints, a marked fibroblastic in- 
vasion of the subsynovial  space and joint capsule was seen 
in the joints of rats  receiving 25 mg/kg per d  GI168. 
Effects  on  Body  Weight.  During  the  2-wk  treatment 
window, vehicle-treated  arthritis rats lost 1% of their body 
weight, whereas normal (no arthritis or treatment) rats in- 
creased their body weight by 29%. Arthritic rats receiving 
GI168 at 25 or 12 mg/kg per d had a 13% increase in body 
weight over the 2 wk of treatment. Indomethacin-treated 
arthritic rats  had a 5%  increase in body weight (Table 3). 
Figure 2.  Radiographic  evidence of the protective  effect of GI168 in 
adjuvant arthritis.  Shown are radiographs of ankle joints from normal rats 
that did not receive adjuvant  (normal) and adjuvant-injected  rats treated 
with either vehicle alone (vehicle) or treated with GI168 at 25 mg/kg per 
(GI168). A joint that is representative  of the group and not an extreme 
case is shown for each group.  These are the same joints from which the 
histology photomicrographs were prepared.  Note the higher bone den- 
sity, the lack of focal areas of severe bone loss, and lesser soft tissue changes 
in the GI168-treated  compared  to the vehicle-treated  rat joint (x3). 
Discussion 
This report shows that an MMP inhibitor is effective  against 
erosive arthritis in vivo. GI168 provided protection against 
a wide spectrum of effects including tissue edema, cartilage 
and bone destruction, abnormal bone deposition, and pannus 
formation. GI168 also had beneficial systemic effects, as indi- 
cated by its positive effects on body weight gain (Table 3). 
Comparison of plasma concentrations and ICs0s for inhi- 
bition of purified MMPs indicates that the GI168 doses used 
here should inhibit collagenase and gelatinase in vivo. At the 
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Percent of group with each score 
Vehicle-  G1168  GI168  G1168 
Radiologic  treated  6  mg/kg  12 mg/kg  26  mg/kg 
Parameter  score"  (n  =  19)  (n  =  6)  (n  =  5)  (n  =  10) 
Edema  0.0-0.5  0  0  0  40 
1.0-1.5  5  17  80  50 
2.0-2.5  58  66  20  10 
3.0-4.0  37  17  0  0 
Mean score*  2.6  2.2  1.6  (P <O.Ot)S  1.0  (P <0.001) 
Bone erosion  0.0-0.5  21  100  100  100 
1.0-1.5  42  0  0  0 
2.0-2.5  32  0  0  0 
3.0-4.0  5  0  0  0 
Mean  score  1.4  0.04  (P <0.05)  0  (P <0.05)  0.1  (P <0.01) 
Bone  0.0-0.5  11  100  100  100 
demineralization  1.0-1.5  63  0  0  0 
2.0-2.5  21  0  0  0 
3.0-4.0  5  0  0  0 
Mean  score  1.5  0.5  (P <0.05)  0.5  (P <0.05)  0.4  (P <0.001) 
Abnormal  0.0-0.5  21  83  100  100 
bone growth  1.0-1.5  63  17  0  0 
2.0-2.5  16  0  0  0 
3.0-4.0  0  0  0  0 
Mean  score  1.2  0.6  0.5  (P <0.05)  0.4  (P <0.01) 
Joint  space  0.0-0.5  21  17  100  100 
narrowing  1.0-1.5  42  83  0  0 
2.0-2.5  32  0  0  0 
3.0-4.0  5  0  0  0 
Mean  score  1.4  0.9  0.5  (P <0.05)  0.3  (P <0.05) 
* Radiologic plates were scored in a blinded fashion from 0 (normal) to 4 (very severe pathology).  See Materials and Methods for details. 
t Scores for individual animals in each group were averaged. 
S Significantly different from vehicle-treated group using Cochran-Mantel Haenszel statistics. 
n  =  Number of rats in each group. 
Dose is mg/kg per d. GI168 was delivered by subcutaneous minipumps. Details are described in Materials and Methods. 
high dose of 25 mg/kg per d, the steady-state concentration 
of unbound  GI168 in the plasma was  100-200  nM,  values 
several-fold above that needed to inhibit rat collagenase (ICs0 
=  15  nM),  human  collagenase  (ICs0  --  3  nM),  human 
gelatinase (IC50  =  3 nM),  and rat gelatinase (100%  inhibi- 
tion at 50 riM). Even though the plasma levels of GI168 are 
near the IC50 for inhibition  of human stromelysin (IC50  = 
225 riM), inhibition of this enzyme in vivo cannot be predicted 
since  the  potency  of GI168  against  rat  stromelysin  is  not 
known.  Use of more selective inhibitors and measurements 
of inhibitor concentrations in the joint in vivo should be helpful 
in further defining which class of MMP is most important 
in protecting  against  arthritis. 
Considerable work has been done to define the relative roles 
of cysteine proteases and MMPs in bone and cartilage resorp- 
tion. Its well established that lysosomal cysteine proteases can 
degrade collagen at low pH (15-17) and that osteoclasts use 
the coordinated secretion of H + and cysteine proteases as a 
mechanism to degrade mineralized bone (29). MMPs are ap- 
parently used by osteoblasts to remove demineralized bone 
(osteoid) from the surface of growing bone, thus preparing 
the surface for osteoclast-mediated degradation  (29).  In the 
453  Conway et al. Figure 3.  Histologic  evidence of the protective effect of GI168 in adjuvant arthritis.  Shown are photomicrographs  of histologic sections of three 
regions within ankle joints from normal rats that did not receive adjuvant (normal) and adjuvant-injected rats treated with either vehicle alone (vehicle) 
or treated with GI168 at 25 mg/kg per d (GI168). A joint that is representative of the group, and not an extreme case, is shown for each group. 
These are the same  joints from which the radiographs were prepared (Fig. 1). Regions shown: (a) distal tibia articulation with talus (x 11); (b) prox/mal 
calcaneus with synovium, which is located behind the Achilles tendon (x 22); (c) a tarsal joint (x44). Note the decrease in edema (E), pannus (large 
arrows), osteoclastic activity in marrow cavities (OC), and ectopic new bone growth (NB)  in the GI168-treated compared to the analogously labeled 
regions in the vehicle-treated arthritic control rat joint. Note also the synovial fibrosis (SF) in the GI168-treated joint, as well as the increased marrow 
cellularity  (small arrowheads) in both vehicle- and GI168-treated joints. 
Table  2.  Effect  of GI168  on  the Histological Parameters of Adjuvant Arthritis 
Percent of group with each  score 
Vehicle-  GI168  GI168  GI168 
Histologic  treated  6  mg/kg  12  mg/kg  25  mg/kg 
Parameter  score  (n  =  19)  (n  =  6)  (n  =  5)  (n  =  10) 
Bone erosion  0-1  11  17  40  70 
2-3  11  50  60  30 
4-5  78  33  0  0 
Mean score*  4.2  3.0  1.8  (P <0.01) S  1.4  (P <0.01) 
Adherent  0-1  11  0  20  40 
osteoclasts  2-3  5  83  80  60 
4-5  84  17  0  0 
Mean  score  4.3  3.0  2.0  (P <0.05)  1.8  (P <0.01) 
Periosteal  0-1  0  0  0  0 
new bone growth  2-3  11  83  100  100 
and remodeling  4-5  89  17  0  0 
continued 
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Percent of group with each score 
Vehicle-  G1168  GI168  GI168 
Histologic  treated  6 mg/kg  12 mg/kg  25 mg/kg 
Parameter  score  (n  =  19)  (n  =  6)  (n  =  5)  (n  ~  10) 
Mean score  4.2  3.2  (P <0.05)  2.4 (P <0.01)  2.7 (P <0.01) 
Cartilage  0-1  21  67  80  70 
destruction  2-3  53  33  20  30 
4-5  26  0  0  0 
Mean score  2.7  1.2  1.0  (P <0.05)  0.8 (P <0.01) 
Pannus  0-1  16  0  60  30 
formation  2-3  0  83  40  60 
4-5  84  17  0  10 
Mean score  3.9  2.5  1.4  (P <0.01)  2.1  (P <0.01) 
Edema  0-1  0  0  0  20 
2-3  21  33  100  80 
4-5  79  67  0  0 
Mean score  4.4  3.7  2.8  (P <0.05)  2.3 (P <0.05) 
Synovial  0-1  26  67  100  100 
lining  2-3  53  0  0  0 
distension  4-5  21  33  0  0 
Mean score  2.3  1.5  0,6  0.2  (P <0.01) 
Synovial  0-1  0  0  0  20 
lining  2-3  63  33  60  70 
necrosis  4-5  37  77  40  10 
Mean score  3.4  3.7  3.2  2.7 
PMN  0-1  0  0  0  0 
infiltration  2-3  16  0  0  40 
4-5  84  100  100  60 
Mean score  4.3  4.8  4.8  3.7 
Lymphocytic  0-1  0  0  0  70 
infiltration  2-3  100  100  100  30 
4-5  0  0  0  0 
Mean score  2.8  3.0  2.8  2.8 
Subsynovial and  0-1  0  0  0  0 
capsular  fibrosis  2-3  95  100  80  40 
4-5  5  0  20  60 
Mean score  2.4  2.3  3.0  3.7 (P <0.01) 
* Slides were scored in a blinded fashion. 0-1, normal to very slight pathology; 2-3, slight to moderate pathology; 4-5, severe to very severe pathology. 
* Scores within each group were averaged. 
S Significantly  different from vehicle-treated  group using Cochran-Mantel Haenszel statistics. 
n  =  Number of rats in each group. 
Dose is mg/kg per d.  G1168 was delivered by subcutaneous  minipumps. Details are described in Materials and Methods. 
455  Conway  et al. Table  3.  Effect  of GII68 and Indomethacin on Body Weight Gain 
Group*  Percent  body weight gain* 
Normal 
AA-vehicle treated 
AA-indomethacin  (1 mg/kg po) 
AA-GI168  (6 mg/kg  sc) 
AA-GI168  (12 mg/kg  sc) 
AA-GI168  (25 mg/kg  sc) 
29.4  +  1.3g (n  =  12) 
-1.3  _+  1.3  (n  =  19) 
5.1  +  1.9 (n  =  12) 
5.1  +_ 2.2 (n  =  5) 
13.8  +  4.6S (n  =  5) 
12.4  _+ 3.2  s (n  =  10) 
* Normals were untreated. AA groups were injected to induce adjuvant 
arthritis. Daily drug doses for days 8-21 are shown in parentheses. 
* Rats were weighed 8 and 21 d after adjuvant injection and percent 
body weight gain was calculated. Data represents mean and SEM of n 
rats per group. 
S Significantly (P <0.05) different from AA-vehicle-treated controls us- 
ing Dunnett's multiple comparison test. 
po, orally; sc, subcutaneously. 
case of cartilage, use of inhibitors suggests that both cysteine 
proteases and MMPs are involved in matrix degradation  in 
vitro (30).  The fact that  GI168 dramatically  inhibits  bone 
and cartilage degradation indicates that MMPs play a central 
role in erosive arthritis  in vivo. Given that many cell types 
produce MMPs (fibroblasts, synovial cells, neutrophils),  it is 
possible that MMPs are in great excess in the arthritic joint 
relative to cysteine proteases, and are thus responsible for the 
bulk of the tissue degradation.  Cysteine proteases may still 
be important  in the cleavage of MMP zymogens to active 
forms (30). 
In the present study, the histopathological evaluation did 
not  show  a  significant  decrease  in  infiltrating  PMNs  or 
mononuclear leukocytes in response to GI168.  In addition, 
synovial fibrosis was not suppressed.  The apparent  lack of 
effect on these inflammation parameters despite the profound 
inhibition of bone and cartilage destruction represents a unique 
antiinflammatory profile. One would expect suppression of 
these parameters if inflammatory cells require MMPs to mi- 
grate into tissue. The observation that MMP inhibition has 
no effect on cellular infiltration  into the joint is consistent 
with a non-MMP recruitment mechanism, such as the produc- 
tion  and action of cytokines. 
With regard to inflammatory cytokines, we recently dis- 
covered that  the  MMP  inhibitor  GI129471  inhibits  LPS- 
induced TNF release from inflammatory cells with an IC50 
of ~50 nM (31).  This data opened up the possibility that 
the efficacy of GI168 against adjuvant arthritis may also in- 
volve inhibition of TNF production. However, GI168 is 15- 
to 20-fold less potent that GI129471 in inhibiting LPS-induced 
TNF release from human and mouse inflammatory cells in 
vitro (Conway, J.  G.,  and G.  M.  McGeehan,  unpublished 
observation). Thus, at steady-state plasma concentrations of 
100-200 nM, one would not expect GI168 to inhibit TNF 
production from inflammatory cells in the arthritic  rats.  It 
is interesting to speculate that an MMP inhibitor with more 
potency  against  TNF  production  will  additionally  block 
inflammatory cell influx and synovial fibrosis.  Recent clin- 
ical reports  of the beneficial effect of anti-TNF  antibody 
therapy in rheumatoid arthritis support this view (32). The 
test of whether MMP inhibitors can prevent trabecular bone 
loss in models that do not have a major inflammatory com- 
ponent, such as ovariectomy-induced osteoporosis in rats, will 
also be enlightening. 
In summary, the present studies show that administration 
of an MMP inhibitor  during 2 wk dramatically suppresses 
cartilage and bone destruction and pannus formation in ad- 
juvant arthritis in rats, suggesting that MMPs mediate joint 
damage in this chronic inflammatory arthritis model. Devel- 
opment of better long-term delivery methods, preferably orally 
active inhibitors, will be necessary to investigate the efficacy 
of MMP  inhibitors  during  the  complete  time  frame  of 
adjuvant-induced early inflammatory changes to severe joint 
deformity beyond 30 d (27, 28). Orally active inhibitors with 
known specificities  against MMPs, including TNF conver- 
tase (31), would greatly facilitate further studies of these en- 
zymes'  roles in arthritis  and other pathologies. 
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